Efficacy analysis of Arbidol treatment in patients with 2019 novel coronavirus pneumonia: a retrospective cohort study.
Ann Palliat Med
; 10(10): 10626-10632, 2021 10.
Article
in English
| MEDLINE | ID: covidwho-1515697
ABSTRACT
BACKGROUND:
The aim of this study was to determine whether Arbidol has a good antiviral effect on coronavirus disease 2019 (COVID-19).METHODS:
A retrospective cohort study was performed in one of the treatment centers for COVID-19 patients in China from January 2020 to March 2020. The antiviral drug Arbidol (ARB) was administrated to some of the patients at 0.2 g tid po for 7 to 10 days. According to whether patients were given ARB, they were divided into 2 groups the ARB group and the Non-ARB group. The primary outcome was the 14-day COVID-19 negativity rate.RESULTS:
Of 146 patients, 140 were included. A total of 79 (56.4%) patients received ARB during hospitalization. In the overall cohort, the time of COVID-19 negativity in the ARB group compared with the Non-ARB group was 12.9 days versus 12.7 days (P=0.175; >0.05). The rates of 14-day COVID-19 negativity were 60.8% and 65.6% in the ARB and non-ARB groups, respectively (P=0.559; >0.05). Using an adjusted model, there were no obvious differences in the time of COVID-19 negativity and the rates of 14-day COVID-19 negativity (P>0.05). According to Kaplan-Meier analysis, the probabilities of 14-day COVID-19 negativity were similar in the 2 groups (log-rank P=0.130; >0.05). In a multivariate Cox analysis, the variables of age [hazard ratio (HR) 0.91, 95% confidence interval (CI) 0.83 to 0.99; P=0.039] and glucose (HR 0.90, 95% CI 0.82 to 0.98; P=0.021) were independently associated with 14-day COVID-19 negativity.CONCLUSIONS:
Our results suggest that there was no apparent favorable clinical response with ARB both in clinical symptoms and the 14-day COVID-19 negativity rate.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Ann Palliat Med
Year:
2021
Document Type:
Article
Affiliation country:
Apm-21-2397
Similar
MEDLINE
...
LILACS
LIS